Why Nanosonics (ASX:NAN) Is Drawing Investor Attention This September

Sonal Goyal

16 September 2026 10:22 AM AEST

Why Nanosonics (ASX:NAN) Is Drawing Investor Attention This September

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Nanosonics (ASX:NAN) has spent close to two decades developing infection-prevention technology focused on automated high-level disinfection of ultrasound probes. The company has expanded beyond its core trophon platform, with CORIS representing an additional technology platform progressing through regulatory and commercial development stages.

The company’s focus remains on expanding its product portfolio while continuing to grow its existing installed base.

Latest Development

Nanosonics reported FY2026 results on 25 August 2026. Revenue increased 3% to A$203.9 million, while revenue at constant currency was A$211.5 million, representing growth compared with the prior period.

Gross Margin was 76.9%, compared with 78.2% previously, with the company attributing the movement to product mix and currency effects.

Reported Earnings before interest and tax declined 10% to A$16.0 million. At constant currency, EBIT was reported at A$21.6 million.

Company Overview

The company designs and manufactures infection-prevention technology, with products manufactured in Australia and sold across international markets.

Its core product, trophon, provides automated high-level disinfection for ultrasound probes. The Business model includes Capital equipment sales as well as Recurring Revenue from consumables and service activities linked to its installed base.

North America remains an important market for Nanosonics, and the company has been listed on the ASX since May 2007.

What Investors May Watch Next

The commercial rollout of CORIS remains an important area to monitor. Adoption rates and expansion into additional markets will provide insight into the platform’s contribution over time.

For trophon, investors may monitor the performance of the existing installed base, equipment upgrades, consumables Demand and service revenue.

Future updates on margins, operating costs and Investment levels will also provide visibility into the company’s earnings trajectory.

Risks

Capital equipment sales can be affected by healthcare spending decisions and hospital budget cycles.

The launch of new products involves regulatory, Manufacturing and customer adoption risks. Revenue contribution from new platforms may take time to develop.

The company is also exposed to currency movements due to its international operations, while competition within infection-prevention markets remains an ongoing factor.

Bottom Line

Nanosonics enters September 2026 with an established infection-prevention platform and continued development of additional products.

FY2026 results highlighted ongoing revenue generation from the existing business while the company continues investing in future growth opportunities.

The progress of CORIS, performance of the trophon platform and management of costs will remain key areas to monitor.

FAQs

Q: What is the ASX ticker for NANOSONICS LIMITED?

A: NANOSONICS LIMITED trades under the ticker (ASX:NAN).

Q: Why is NANOSONICS LIMITED in focus?

A: The article explains the company developments, operating context and key factors relevant to its current ASX profile.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.